Comparison of Propylthiouracil vs Methimazole for Thyroid Storm in Critically Ill Patients
JAMA Network Open · 2023
DOI: 10.1001/jamanetworkopen.2023.8655 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Network Open, 2023. Verfasst von Sun Y Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Endocrinology, Diabetes, Nutrition & Weight Management, Boston University Chobanian & Avedisian School of Medicine…. Hauptthemen laut MEDLINE: Methimazole, Thyroid Crisis. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Importance Thyroid storm is the most severe form of thyrotoxicosis, with high mortality, and is treated with propylthiouracil and methimazole. Some guidelines recommend propylthiouracil over methimazole, although the difference in outcomes associated with each treatment is unclear.
Objective
To compare outcomes associated with use of propylthiouracil vs methimazole for the treatment of thyroid storm. Design, Setting, and Participants This comparative effectiveness study comprised a large, multicenter, US-based cohort from the Premier Healthcare Database between January 1, 2016, and December 31, 2020. It included 1383 adult patients admitted to intensive or intermediate care units with a diagnosis of thyroid storm per International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes and treated with either propylthiouracil or methimazole. Analyses were conducted from July 2022 to February 2023. Exposure Patients received either propylthiouracil or methimazole for treatment of thyroid storm. Exposure was assigned based on the initial thionamide administered. Main Outcomes and Measures The primary outcome was the adjusted risk difference of in-hospital death or discharge to hospice between patients treated with propylthiouracil and those treated with methimazole, assessed by targeted maximum likelihood estimation.
Results
A total of 1383 patients (656 [47.4%] treated with propylthiouracil; mean [SD] age, 45 [16] years; 473 women [72.1%]; and 727 [52.6%] treated with methimazole; mean [SD] age, 45 [16] years; 520 women [71.5%]) were included in the study. The standardized mean difference for age was 0.056, and the standardized mean difference for sex was 0.013. The primary composite outcome occurred in 7.4% of of patients (102 of 1383; 95% CI, 6.0%-8.8%). A total of 8.5% (56 of 656; 95% CI, 6.4%-10.7%) of patients who initiated propylthiouracil and 6.3% (46 of 727; 95% CI, 4.6%-8.1%) who initiated methimazole died in the hospital (adjusted risk difference, 0.6% [95% CI, −1.8% to 3.0%]; P = .64). There were no significant differences in duration of organ support, total hospitalization costs, or rates of adverse events between the 2 treatment groups. Conclusion and Relevance In this comparative effectiveness study of a multicenter cohort of adult patients with thyroid storm, no significant differences were found in mortality or adverse events in patients who were treated with propylthiouracil or methimazole. Thus, current guidelines recommending propylthiouracil over methimazole for treatment of thyroid storm may merit reevaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Section of Endocrinology, Diabetes, Nutrition & Weight Management, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
- Department of Medicine, The Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
Förderung
- NIEHS NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Lee, S. Y., Modzelewski, K. L., Law, A. C., Walkey, A. J., Pearce, E. N., & Bosch, N. A. (2023). Comparison of Propylthiouracil vs Methimazole for Thyroid Storm in Critically Ill Patients. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.8655
Vancouver
Lee SY, Modzelewski KL, Law AC, Walkey AJ, Pearce EN, Bosch NA. Comparison of Propylthiouracil vs Methimazole for Thyroid Storm in Critically Ill Patients. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.8655
BibTeX
@article{Lee2023,
author = {Lee, Sun Y and Modzelewski, Katherine L and Law, Anica C and Walkey, Allan J and Pearce, Elizabeth N and Bosch, Nicholas A},
title = {Comparison of Propylthiouracil vs Methimazole for Thyroid Storm in Critically Ill Patients},
journal = {JAMA Network Open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.8655}
}
EUVIMED